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ABSTRACT 
Glycosylation	is	a	complex	form	of	protein	modification	occurring	in	the	secretory	
pathway.	The	addition	of	N‐	and	O‐glycans	affects	intracellular	processes	like	the	folding	
and	trafficking	of	most	glycoproteins.	To	better	understand	the	impact	of	glycosylation	
in	protein	folding	and	maturation,	parameters	like	glycosylation	site	occupancy	and	
oligosaccharide	structure	must	be	measured	quantitatively.	In	the	present	chapter,	we	
describe	current	methods	enabling	the	determination	of	N‐glycosylation	by	assessment	
of	cellular	dolichol‐phosphate	levels,	dolichol‐linked	oligosaccharides	and	the	occupancy	
of	N‐glycosylation	sites.	We	also	provide	detailed	methods	for	the	analysis	of	O‐
glycosylation,	whose	role	in	intracellular	protein	maturation	is	often	overlooked.	
	
1. INTRODUCTION 
Glycosylation	is	a	widespread	and	complex	form	of	modification,	which	adds	signals	and	
specific	functions	to	glycoproteins.	N‐linked	and	O‐linked	glycosylation,	which	are	the	
main	forms	of	protein	glycosylation,	are	structurally	and	functionally	distinct.	N‐linked	
glycosylation	is	initiated	in	the	endoplasmic	reticulum	(ER),	where	the	oligosaccharide	
GlcNAc2Man9Glc3	is	transferred	co‐translationally	to	selected	asparagine	residues	of	
nascent	glycoproteins.	While	still	in	the	ER,	oligosaccharides	on	glycoproteins	are	
trimmed	by	glucosidase	and	mannosidase	enzymes	to	GlcNAc2Man8.	Later	in	the	Golgi	
apparatus	N‐linked	oligosaccharides	undergo	further	trimming	and	elongation	steps,	
which	contribute	to	the	structural	diversity	of	N‐linked	glycosylation.	In	contrast	to	the	
co‐translational	beginning	of	N‐glycosylation,	O‐linked	glycosylation	takes	place	on	
folded	proteins	and	is	initiated	by	the	transfer	of	monosaccharides	to	serine	and	
threonine	residues.	Some	forms	of	O‐glycosylation	like	O‐fucosylation	(Harris	and	
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Spellman,	1993)	and	O‐mannosylation	(Lommel	and	Strahl,	2009)	begin	in	the	ER,	
whereas	mucin‐type	O‐glycosylation	(Tian	and	Ten	Hagen,	2009)	and	the	biosynthesis	of	
glycosaminoglycan	chains	(Bishop	et	al.,	2007)	begin	in	the	Golgi	apparatus.	
N‐glycosylation	is	important	for	the	folding	and	trafficking	of	many	glycoproteins	
(Helenius	and	Aebi,	2004).	The	inhibition	of	N‐linked	glycosylation,	for	example	by	
tunicamycin,	results	in	the	accumulation	of	misfolded	proteins	in	the	ER,	which	is	a	
strong	stimulus	of	the	UPR	(Shamu	et	al.,	1994).	After	trimming	by	glucosidase‐I	in	the	
ER,	N‐linked	oligosaccharides	are	bound	by	the	chaperone	proteins	calnexin	and	
calreticulin,	which	contribute	to	the	folding	of	glycoproteins	(Ellgaard	et	al.,	1999).	
Furthermore,	N‐linked	oligosaccharides	are	also	recognized	by	the	EDEM	protein,	which	
redirects	misfolded	proteins	from	the	ER	lumen	to	the	cytosol	for	proteasome‐mediated	
degradation.	Another	important	signal	carried	by	N‐linked	oligosaccharides	is	the	
mannose‐6‐phosphate	epitope,	which	mediates	the	recognition	and	transfer	of	
lysosomal	proteins	to	their	target	organelle	(Dahms	et	al.,	1989).	
The	most	common	form	of	O‐glycosylation,	i.e.	mucin‐type	glycosylation,	does	not	
contribute	to	glycoprotein	folding	since	it	occurs	in	the	Golgi	apparatus.	However,	the	
trafficking	and	secretion	of	some	glycoproteins	requires	proper	mucin‐type	
glycosylation,	as	demonstrated	in	the	case	of	the	hormone	FGF23.	Deficient	initiation	of	
mucin‐type	O‐glycosylation	alters	the	susceptibility	of	FGF23	to	Golgi‐localized	
proteases,	thereby	inhibiting	the	maturation	of	active	FGF23.	Mucin‐type	glycosylation	
of	FGF23	is	initiated	by	the	polypeptide	N‐acetylgalactosaminyltransferase‐3	enzyme.	
Loss	of	this	enzymatic	activity	leads	to	the	disease	tumoral	calcinosis,	which	is	also	
caused	by	FGF23	deficiency	(Chefetz	and	Sprecher,	2009).	
Another	example	of	glycosyltransferase‐assisted	trafficking	is	given	by	the	OFUT1	O‐
fucosyltransferase	enzyme.	This	ER‐localized	glycosyltransferase	adds	fucose	to	the	
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EGF‐like	repeats	of	proteins	such	as	Notch	and	its	ligands.	Independent	from	its	
glycosyltransferase	activity,	OFUT1	also	acts	as	a	chaperone,	which	is	essential	for	the	
transfer	of	Notch	from	the	ER	to	the	Golgi	apparatus	(Okajima	et	al.,	2005).	The	
contribution	of	O‐linked	glycosylation	to	glycoprotein	folding	and	secretion	is	much	less	
documented	than	in	the	case	of	N‐linked	glycosylation.	This	limited	knowledge	is	
certainly	related	to	the	technically	difficult	investigation	of	O‐linked	glycan	structures.	In	
fact,	O‐linked	glycans	are	often	densely	clustered	and	these	glycans	cannot	be	released	
without	significantly	altering	the	polypeptide	backbone.	The	O‐glycanase	enzyme	from	
Streptococcus	pneumoniae	has	a	specificity	limited	to	the	O‐linked	disaccharide	Gal(1‐
3)GalNAc‐O.	By	contrast,	N‐linked	glycans	can	be	conveniently	cleaved	at	the	first	
GlcNAc	unit	by	the	N‐glycosidase	F.		
	
2. N‐GLYCOSYLATION  
Proper	N‐linked	glycosylation	is	required	for	folding	and	intracellular	trafficking	of	
glycoproteins.	Deficiency	in	the	biosynthesis	of	the	precursor	of	N‐glycans	or	in	the	
processing	of	N‐glycans	in	the	ER	can	alter	glycoprotein	folding	and	induce	UPR.	The	
following	methods	can	be	applied	to	identify	defects	of	oligosaccharide	assembly	and	of	
N‐glycosylation	site	occupancy	in	target	cells.		
	
2.1. Dolichol phosphate analysis 
The	oligosaccharide	core	consisting	of	GlcNAc2Man9Glc3	is	first	assembled	on	the	
polyisoprenoid	carrier	dolichol	(Dol).	Moreover,	dolichol‐phosphate	(Dol‐P)	is	also	part	
of	the	glycosylation	substrates	Dol‐P‐Man	and	Dol‐P‐Glc,	which	account	for	the	final	
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extension	of	the	oligosaccharide	core	in	the	ER.	Considering	the	low	levels	of	Dol‐P	
based	structures	in	cells,	a	sensitive	Dol‐P	detection	can	be	achieved	by	labeling	with	the	
fluorescent	compound	9‐anthryldiazomethane.	The	procedure	was	originally	described	
for	tissue	sample	extraction	(Elmberger	et	al.,	1989)	and	we	have	adapted	the	method	
for	cultured	cells	(Haeuptle	et	al.,	2009).	Detection	of	unlabeled	Dol‐P	can	also	be	
achieved	by	negative	ion	electrospray	mass	spectrometry	(ESI‐MS),	which,	in	
combination	to	precursor	ion	fragmentation,	provides	detailed	information	on	Dol‐P	
composition	and	on	the	saturation	state	of	the	‐isoprene	unit.		
	
2.1.1. Required materials 
Devices	and	materials	
- LaChrom	D‐7000	HPLC	system	(Merck),	equipped	with	an	Inertsil	ODS‐3	column	
(5	μm,	4.6	x	250	mm;	GL	Sciences	Inc.,	Japan)	with	a	precolumn	and	a	LaChrom	
7485	fluorescence	detector.	
- Nano‐flow	ESI‐ion	trap	MS	(Eksigent	nano‐LC,	3200	QTRAP‐MS,	AB/SCIEX)	
- C18	Sep‐Pak	and	Silica	Sep‐Pak	cartridges	(Waters)	
Other	reagents	
- 9‐anthryldiazomethane	(ADAM)	(Sigma‐Aldrich)	
- C80‐polyprenol	and	C95‐Dol‐P	standards	(Larodan	Fine	Chemicals,	Sweden)	
- Diazald	(Sigma‐Aldrich)	
- Carbitol	(Sigma‐Aldrich)	
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2.1.2. Extraction and purification of Dol and Dol‐P 
Adherent	cells	(about	3	x	108	cells)	are	washed	in	PBS	after	trypsinization	and	
resuspended	in	6	ml	of	water	and	then	fixed	by	addition	of	6	ml	of	methanol.	The	
resulting	suspension	is	transferred	to	a	round	bottom	glass	flask	and	3	ml	of	15	M	
potassium	hydroxide	are	added	for	alkaline	hydrolysis.	An	aliquot	of	the	C80	polyprenyl‐
phosphate	(e.g.	15	g)	can	be	added	as	internal	standard	for	subsequent	quantification.	
The	round	bottom	flask	is	attached	to	a	reflux	cooler	and	incubated	in	a	preheated	oil	
bath	at	100	°C	for	1	h.	This	alkaline	hydrolysis	removes	carbohydrates	from	the	Dol‐P	
carrier.	The	resulting	lysate	is	transferred	to	a	glass	tube	and	methanol	is	added	to	a	
total	volume	of	15	ml.	The	suspension	is	mixed	with	30	ml	of	
methanol/dichloromethane	(1:4,	v:v)	and	incubated	at	40	°C	for	1	h.	Discard	the	upper	
phase	(methanol)	and	transfer	the	lower	phase	(dichloromethane)	containing	the	
extracted	lipids	to	a	glass	tube	suitable	for	centrifugation.	Wash	the	organic	phase	with	
10	ml	of	dichloromethane/methanol/water	(3:48:47,	v:v:v).	For	phase	separation,	
centrifuge	at	6800	x	g	at	room	temperature	for	10	min	and	discard	the	upper	phase.	
Repeat	this	washing	step	four	times,	which	ensures	the	removal	of	free	sugars	and	salt	
from	the	sample.	The	organic	phase	is	then	dried	under	nitrogen	gas.	
Dol	and	Dol‐P	are	purified	in	two	steps	using	C18‐	and	silica‐based	chromatography	
resins.	First,	equilibrate	the	C18	Sep‐Pak	cartridge	with	5	ml	of	methanol,	followed	by	5	
ml	of	chloroform/methanol	(2:1,	v:v)	and	10	ml	of	methanol/water	(98:2,	v:v,	
supplemented	with	20	mM	phosphoric	acid).	The	dried	lipids	from	the	extraction	step	
are	dissolved	in	400	μl	of	chloroform/methanol	(2:1,	v:v)	and	diluted	by	adding	10	ml	of	
methanol/water	(98:2,	v:v)	supplemented	with	20	mM	phosphoric	acid.	Load	the	
solution	onto	the	C18	Sep‐Pak	cartridge	and	wash	with	20	ml	of	methanol/water	(98:2,	
v:v,	supplemented	with	20	mM	phosphoric	acid).	To	remove	phosphoric	acid	from	the	
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cartridge,	wash	again	with	10	ml	of	methanol/water	(98:2,	v:v)	devoid	of	phosphoric	
acid.	Dol	and	Dol‐P	can	be	eluted	with	20	ml	of	chloroform/methanol	(2:1,	v:v)	and	
collected	in	a	new	glass	tube.	The	eluate	should	be	neutralized	by	adding	100	μl	of	25%	
ammonium	hydroxide.	
The	second	purification	step	through	Silica	Sep‐Pak	cartridges	allows	the	separation	of	
Dol	from	Dol‐P.	First,	equilibrate	the	cartridge	with	10	ml	of	
chloroform/methanol/water	(10:10:3,	v:v:v)	and	40	ml	of	chloroform/methanol	(2:1,	
v:v,	in	0.5%	ammoniumhydroxide).	Place	a	new	glass	tube	to	collect	the	dolichol	
fraction,	which	will	be	in	the	flowthrough	of	the	chromatography.	Apply	the	neutralized	
eluate	from	the	previous	step	onto	the	Silica	Sep‐Pak	cartridge.	Rinse	the	glass	tube	of	
the	eluate	with	10	ml	chloroform/methanol	(2:1,	v:v,	in	0.5%	ammoniumhydroxide)	and	
load	it	onto	the	Silica	cartridge.	Repeat	the	process	with10	ml	chloroform/methanol	
(2:1,	v:v,	in	0.5%	ammonium	hydroxide).	Elute	Dol‐P	into	another	glass	tube	by	applying	
30	ml	chloroform/methanol/water	(10:10:3,	v:v:v)	onto	the	Silica	cartridge.	Dry	the	Dol	
and	Dol‐P	fractions	under	nitrogen	gas	at	50	°C.	
	
2.1.3. Anthryldiazomethane labeling of Dol‐P 
Dol‐P	labeling	is	made	in	two	steps.	First,	Dol‐P	is	dimethylated	and	then	selectively	
demethylated	to	produce	monomethylated	Dol‐P	(Dol‐P‐Me).	The	procedure	yields	an	
enhanced	fluorescence	signal	when	labeling	Dol‐P‐Me	with	9‐anthryl	derivatives	
(Yamada	et	al.,	1986).	The	second	step	is	the	derivatization	of	Dol‐P‐Me	with	9‐
anthryldiazomethane	(ADAM).	We	use	the	diazomethane	generator	system	(Sigma‐
Aldrich)	for	the	dimethylation	of	Dol‐P1.	It	consists	of	two	glass	tubes:	a	small	internal	
tube	placed	inside	a	larger	outer	tube.	The	dried	Dol‐P	fraction	is	first	dissolved	in	1	ml	
                                                     
1 Diazomethane is very toxic in contact with eye, skin or by inhalation. Diazomethane may explode in contact 
with sharp edges and when heated beyond 100 °C. 
8 
 
of	diethylether	and	transferred	into	the	large	outer	glass	tube	of	the	diazomethane	
generator.	The	glass	that	contained	the	Dol‐P	fraction	is	washed	twice	with	1	ml	of	
diethylether,	which	is	added	to	the	outer	tube	of	the	diazomethane	generator.	To	
produce	diazomethane,	add	0.367	g	Diazald	(explosive!)	to	the	inner	tube	of	the	
diazomethane	generator	system.	Dissolve	Diazald	by	addition	of	1	ml	of	Carbitol.	
Assemble	the	two	parts	of	the	diazomethane	generator	system	and	immerse	it	into	an	
ice	bath.	Make	sure	that	the	generator	system	is	sealed.	Using	a	syringe,	carefully	add	1.5	
ml	of	37%	potassium	hydroxide	dropwise	to	the	inner	tube	of	the	diazomethane	
generator	system.	Add	few	drops	first	and	wait	until	the	reaction	starts,	as	seen	by	
formation	of	gaseous	diazomethane	in	the	Diazald	solution.	In	this	way,	the	content	of	
the	inner	tube	is	prevented	from	spilling	into	the	outer	tube.	Then,	carefully	add	the	rest	
of	the	potassium	hydroxide.	Gently	mix	the	reactants	and	incubate	the	reaction	for	1	h	in	
the	ice	bath.	The	diethylether	phase	containing	Dol‐P	should	turn	yellow	by	then,	
indicating	an	excess	of	diazomethane.	After	disassembly	of	the	diazomethane	generator,	
leftover	reactants	can	be	neutralized	by	addition	of	0.15	g	of	silicic	acid	to	the	inner	tube.		
The	outer	tube	should	be	sealed	with	parafilm	and	left	for	2	h	at	room	temperature.	The	
Dol‐P‐Me2	solution	is	transferred	to	a	glass	extraction	tube	and	dried	under	nitrogen	
gas.	To	selectively	demethylate	Dol‐P‐Me2,	dissolve	it	in	4	ml	of	tert‐butylamine	and	
incubate	at	70	°C	for	14	h.	Make	sure	to	seal	the	extraction	tube	completely	to	prevent	
the	loss	of	tert‐butylamine.	Then,	evaporate	tert‐butylamine	under	nitrogen	gas	and	
dissolve	Dol‐P‐Me	in	1.5	ml	of	0.1	M	hydrochloric	acid	adjusted	to	pH	3	with	sodium	
hydroxide.	Extract	Dol‐P‐Me	twice	with	3	ml	of	diethylether	and	dry	the	combined	
extracts	under	nitrogen	gas.	Labeling	is	performed	in	1	ml	of	diethylether	saturated	with	
ADAM.	Prepare	the	ADAM	solution	in	a	separate	glass	tube	by	gradually	adding	the	
reddish	ADAM	powder	to	0.7	ml	of	diethylether	until	saturation.	Take	600	μl	of	the	
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yellowish	ADAM	solution	and	add	it	to	the	dried	Dol‐P‐Me	fraction.	Incubate	the	labeling	
reaction	at	4	°C	in	the	dark	for	8h.	After	drying	under	nitrogen	gas,	dissolve	the	reaction	
products	in	2.4	ml	of	n‐hexane.	Wash	the	hexane	phase	three	times	with	1.8	ml	of	
acetonitrile.	Discard	each	time	the	acetonitrile	lower	phase.	Dry	the	n‐hexane	phase	
under	nitrogen	gas.	The	ADAM	labeled	Dol‐P‐Me	fraction	can	be	dissolved	in	
acetonitrile/dichloromethane	(3:2,	v:v)	for	HPLC	analysis.	
	
2.1.4. HPLC analysis of fluorescently labeled Dol‐P 
ADAM‐derivatized	Dol‐P	are	separated	by	HPLC	using	an	Intertsil	ODS‐3	column	and	
applying	isocratic	elution	according	to	Yamada	et	al.	(Yamada	et	al.,	1986).	The	mobile	
phase	consists	of	acetonitrile/dichloromethan	(3:2,	v:v)	supplemented	with	0.01%	
diethylamine.	ADAM	fluorescence	is	detected	at	412	nm	using	an	excitatory	wavelength	
of	365	nm.	
	
2.1.5. Negative ion electrospray mass spectrometry of Dol‐P 
Purified	Dol‐P	can	also	be	directly	analyzed	by	ESI‐MS	(Haeuptle	et	al.,	2009)	without	
derivatization.	The	dried	Dol‐P	sample	is	first	dissolved	in	90%	acetonitrile,	10%	n‐
hexane,	containing	0.01%	diethylamine,	and	then	vortexed	and	centrifuged	to	eliminate	
any	particulate	matter.	The	nano‐flow	system	consists	of	an	injector	fitted	with	a	10	l	
fused	silica	capillary	loop,	coupled	in‐line	to	a	nano‐flow	pump	and	emitter	tip	of	a	nano‐
electrospray	ion	source	via	20	m	ID	fused	silica	capillary	tubing.	An	aliquot	of	the	
sample	is	loaded	into	the	injector	loop	and	switched	in‐line	to	the	nano‐flow	system,	
introducing	the	sample	directly	into	the	ion	source	with	the	dissolution	solvent	at	a	flow	
rate	of	400	nl/min.	Using	a	3200	AB/Sciex	QTRAP	MS,	all	mass	spectra	are	acquired	
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manually	in	the	Enhanced	MS	scan	mode	(ion	trapping	mode),	scanning	from	m/z	1000	
to	m/z	1700	at	a	scan	rate	of	1000	amu/sec	and	a	step	size	of	0.06	amu.	The	curtain	gas	
flow	is	maintained	at	10	psi,	collision	gas	pressure	at	4	x	10e‐5	torr	(High),	interface	
heater	temperature	at	150	°C,	declustering	potential	at	‐200V,	entrance	potential	at		‐
10V,	collision	energy	at	‐10V	and	the	ion	spray	voltage	is	varied	between	‐2400	and	‐
4500	V,	depending	on	the	condition	of	the	emitter	needle.	Fragment	ion	spectra	of	
selected	Dol‐P	precursor	masses	are	acquired	in	the	Enhanced	Product	Ion	mode	(EPI	
mode,	fragmentation	in	ion	trapping	mode)	with	the	collision	energy	set	to	‐100V	and	
linear	scanning	starting	at	m/z	100.	Extensive	rinsing	of	the	nano‐flow	system	in	
between	sample	injections	is	necessary	to	avoid	cross	contamination.	
	
2.2. Dolichol‐linked oligosaccharide analysis 
Defects	of	Dol‐linked	oligosaccharide	(DLO)	assembly	decrease	the	availability	of	the	
mature	Dol‐PP‐GlcNAc2Man9Glc3	core	for	glycosylation	of	acceptor	Asn	sites	on	nascent	
glycoproteins	(Hulsmeier	et	al.,	2007).	Such	a	DLO	shortage	leads	to	the	non‐occupancy	
of	N‐glycosylation	sites,	which	impacts	on	protein	folding	and	trafficking	(Helenius	and	
Aebi,	2004).	DLOs	are	conveniently	analyzed	either	by	metabolic	labeling	using	[3H]‐
mannose,	or	by	derivatization	with	the	fluorochrome	2‐aminobenzamide	(2AB).	The	
extraction,	hydrolysis,	and	purification	procedure	of	DLOs	is	common	to	both	methods.	
	
2.2.1. Required materials 
Chemicals	
In	addition	to	the	solvents	mentioned	in	section	0,	you	need	the	reagents	listed	below.	
- 3H‐labeled		D‐mannose,	5	mCi	(Hartmann	Analytics,	Germany)	
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- 2‐Propanol	(Sigma‐Aldrich)	
- Trizma	base	(Sigma‐Aldrich)	
- 2‐Aminobenzamide	(Sigma‐Aldrich)	
- Sodium	cyanoborohydride	NaBH3CN,	(Sigma‐Aldrich)	
Devices	and	other	materials	
- Dowex	AG	1	x	4,	Dowex	AG	50	x	8	(Bio‐Rad)	
- ENVI‐C18	and	ENVI‐Carb	resin	(Supelco)	
- Ultrafree‐MC	centrifugal	filter	devices	(Millipore,	Cat.	No.:	UFC30LH25)	
- Supelcosil	LC‐NH2	column,	5	μm	particle	size,	250	x	4.6	mm	(Supelco)	
- Scintillation	flow	monitor	FLO‐ONE	A‐525	(Packard)	
	
2.2.2. [3H]‐labeling of DLOs 
Approximately	2	x	108	are	washed	three	times	with	PBS	to	remove	Glucose	from	the	
medium.	Cells	are	then	incubated	in	DMEM	without	serum	and	glucose	at	37	°C	for	45	
min.	After	this	starving	step,	[3H]‐mannose	(125	μCi	/	108	cells)	is	added	to	the	cells,	
which	are	incubated	further	at	37	°C	for	1	h.		
	
2.2.3. Extraction of DLOs 
The	labeling	medium	is	aspirated	and	cells	are	washed	quickly	with	13	ml	of	ice‐cold	
PBS.	Cells	are	then	fixed	by	adding	11	ml	of	ice‐cold	methanol/0.1	M	Tris‐HCl	(8:3,	v:v)	
and	collected	by	scraping	when	dealing	with	adherent	cells.	The	cell	suspension	is	
transferred	to	a	50	ml	conical	tube	and	12	ml	of	chloroform	are	added.	After	vigorous	
mixing	using	a	vortex,	the	suspension	is	centrifuged	at	6000	x	g	for	10	min.	The	upper	
methanol	phase	and	the	lower	chloroform	phases	are	discarded,	while	the	interface	
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precipitate	is	kept	for	further	extraction	of	DLOs.	To	this	end,	add	3	ml	of	
chloroform/methanol/water	(10:10:3,	v:v:v),	vortex	for	2	min	and	spin	at	6000	x	g	for	
10	min.	Transfer	the	supernatant	to	a	glass	extraction	tube.	Repeat	the	extraction	three	
times	using	2	ml	of	chloroform/methanol/water	(10:10:3,	v:v:v).	Then	dry	the	extracted	
DLOs	under	nitrogen	gas.	
	
2.2.4. Hydrolysis and purification of oligosaccharides 
Acid	hydrolysis	is	used	to	release	the	oligosaccharide	from	the	lipid	carrier.	For	this,	
incubate	the	extracted	DLOs	in	2	ml	of	0.1	M	hydrochloric	acid	(in	50%	2‐propanol)	at	
50	°C	for	1	h,	then	neutralize	by	adding	1	ml	of	0.2	M	NaOH.	To	purify	oligosaccharides,	
prepare	a	disposable	chromatography	column	with	1ml	of	Dowex	AG	1x4	resin,	followed	
by	0.6	ml	of	Dowex	AG	50x8	resin.	Equilibrate	the	column	with	20	ml	of	30%	2‐propanol	
and	apply	the	3	ml	hydrolyzate,	then	wash	with	3	ml	of	30%	2‐propanol.	Collect	the	
flowthrough	(6	ml	total)	into	a	new	glass	tube	and	evaporate	under	nitrogen	gas.	A	
second	column	system	is	used	to	further	purify	the	DLOs.	Prepare	a	column	with	0.2	ml	
of	ENVI‐C18	resin	and	1	ml	of	ENVI‐Carb	120/400	resin.	Place	a	C18	Sep‐Pak	cartridge	on	
top	of	the	prepared	column.	Wash	the	system	with	5	ml	of	100%	methanol,	5	ml	of	
100%	acetonitrile	and	5	ml	of	water/acetonitrile/0.1	M	ammonium	acetate.	Finally,	
equilibrate	with	9	ml	of	2%	acetonitrile/0.1	M	ammonium	acetate.	Resuspend	the	dried	
oligosaccharide	sample	in	1	ml	of	acetonitrile/0.1	M	ammonium	acetate	and	apply	it	
onto	the	column.	Wash	the	sample	vial	with	1	ml	of	acetonitrile/0.1	M	ammonium	
acetate,	which	is	then	loaded	onto	the	column.	Make	sure	that	the	lower	ENVI	resin	
column	does	not	run	dry	during	the	loading	process.	Wash	the	column	system	with	9	ml	
of	acetonitrile/0.1	M	ammonium	acetate.	To	elute	DLOs,	add	6	ml	of	water/acetonitrile	
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(3:1,	v:v)	and	collect	the	eluate	in	a	new	glass	tube.	Water	and	acetonitrile	are	then	
removed	from	the	pure	oligosaccharide	sample	by	evaporation	under	nitrogen	gas.	
	
2.2.5. HPLC analysis of [3H]‐labeled oligosaccharides 
A	Supelco	LC‐NH2	normal	phase	column	(including	a	LC‐NH2	guard	column)	and	a	two	
solvent	system	are	used	for	HPLC	separation	(Zufferey	et	al.,	1995).	Prepare	
acetonitrile/water	(7:3,	v:v)	and	acetonitrile/water	(1:1)	as	mobile	phases.	Dissolve	the	
purified	oligosaccharides	in	50‐100	μl	water	for	injection.	The	separation	is	carried	out	
by	running	a	gradient	from	acetonitrile/water	(7:3,	v:v)	to	acetonitrile/water	(1:1)	over	
75	min	at	a	flow	rate	of	1	ml/min.	The	[3H]‐labeled	oligosaccharides	are	detected	using	a	
flow	scintillation	detector.	When	the	level	of	[3H]‐incorporation	is	too	low	for	detection	
by	flow	scintillation,	fractions	of	the	HPLC	run	can	be	collected	and	measured	separately	
in	a	scintillation	counter	(Müller	et	al.,	2005).	While	more	time	consuming,	the	latter	
detection	yields	a	superior	signal	to	noise	ratio.	
	
2.2.6. 2‐aminobenzamide labeling of DLOs 
The	labeling	of	oligosaccharides	with	2‐aminobenzamide	(2AB)	is	performed	according	
to	Bigge	et	al.	(Bigge	et	al.,	1995).	For	2AB	labeling,	DLOs	are	extracted	as	described	
under	section	0 and	oligosaccharides	are	purified	as	outlined	under	section	0.	Dried	
oligosaccharides	are	resuspended	in	200	μl	water/acetonitrile	(3:1,	v:v)	and	transferred	
to	a	1.5	ml,	screw	cap	Eppendorf	tube,	where	they	are	dried	again.	The	2AB	labeling	
reagent	is	prepared	by	dissolving	24	mg	2AB	in	500	μl	acetic	acid/DMSO	(3:7,	v:v)	and	
adding	31	mg	sodium	cyanoborohydride,	thereby	achieving	a	0.35	M	2AB	and	1	M	
sodium	cyanoborohydride	solution.	Add	20	μl	of	the	labeling	reagent	to	the	dried	
oligosaccharides,	mix	by	vortexing	and	incubate	at	65	°C	for	2	h.	After	cooling,	add	380	
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μl	acetonitrile	to	the	sample.	Excess	labeling	reagent	is	removed	using	the	paper	disk	
clean	up	procedure	(Müller	et	al.,	2005).To	this	end,	punch	paper	disks	from	a	Whatman	
3MM	paper	using	an	office	hole	puncher.	Place	two	paper	disks	in	a	centrifugal	filter	
device	and	wash	with	450	μl	of	water	by	spinning	30	s	at	2000	x	g.	Wash	the	filter	twice	
with	450	μl	95%	acetonitrile	and	load	the	labeled	samples.	Let	the	sample	pass	through	
the	paper	disks	without	spinning	the	filter	device.	Wash	six	times	with	450	μl	95%	
acetonitrile	followed	by	a	quick	spin	at	2000	x	g.	Elute	the	labeled	oligosaccharides	by	
applying	three	times	50	μl	of	water	and	spinning	briefly	at	2000	x	g.	
	
2.2.7. HPLC analysis of 2AB‐labeled oligosaccharides 
To	separate	2AB‐labeled	oligosaccharides,	we	have	adapted	the	procedure	of	Royle	et	al.	
(Royle	et	al.,	2002)	using	a	three	buffer	solvent	system	(Grubenmann	et	al.,	2004).	We	
use	a	GlykoSep‐N	column	maintained	at	30	°C.	Solvent	A	consists	of	80%	acetonitrile	
with	10	mM	formic	acid	(pH	4.4)	and	solvent	B	of	40%	acetonitrile	with	30	mM	formic	
acid	(pH	4.4).	The	50	mM	formic	acid	stock	solution	is	adjusted	to	pH	4.4	with	
ammonium	hydroxide.	Solvent	C	is	0.5%	formic	acid	(pH	is	not	adjusted).	The	gradient	is	
run	from	100%	solvent	A	to	100%	solvent	B	over	160	min	at	a	flow	rate	of	0.4	ml/min.	A	
transition	from	100%	solvent	B	to	100%	solvent	C	follows	within	2	min	at	a	flow	rate	of	
1	ml/min.	
	
2.3. N‐glycosylation Site Occupancy 
Most	defects	of	N‐glycosylation	result	in	partial	occupancy	of	N‐glycosylation	sites	on	
proteins.	The	quantitative	analysis	of	glycosylation	site	occupancy	is	not	trivial	because	
glycosylated	glycosylation	sites	usually	ionize	less	efficiently	than	native	peptides	and	it	
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is	not	feasible	to	synthesize	adequate	standard	glycopeptides	for	quantification	
purposes.	Due	to	the	structural	microheterogenity	of	glycopeptides	the	relatively	low	
sensitivity	in	detection	is	further	compromised.	Therefore,	we	developed	a	strategy	to	
simplify	the	analysis	and	quantification	of	glycosylation	site	occupancy	by	
deglycosylating	the	N‐linked	glycopeptides	with	N‐glycosidase	F.	As	an	example,	we	
describe	here	the	analysis	of	human	serum	transferrin,	which	carries	two	N‐glycans	at	
Asn413	and	Asn611.	We	showed	previously	that	Asn611	glycosylation	is	most	sensitive	to	
cellular	stress	imposed	by	congenital	disorders	of	glycosylation	or	alcohol	abuse	
(Hulsmeier	et	al.,	2007).	Serum	transferrin	is	immune‐affinity	purified	from	5	l	serum,	
proteolytically	digested	and	N‐glycans	are	removed	by	digestion	with	N‐glycosidase	F,	
which	converts	the	corresponding	glycosylated	Asn	to	Asp.	N‐glycosidase	F	digestion	in	
buffer	constituted	with	isotopic	water	(H218O)	leading	to	the	incorporation	of	18O	into	
the	respective	Asp,	which	allows	to	monitor	for	potential	spontaneous	deamination	of	
unoccupied	Asn	prior	to	digestion	with	N‐glycosidase	F.	The	inclusion	of	isotopic	labeled	
standard	peptide	enables	sensitive	and	accurate	quantitation	of	deglycosylated	versus	
unoccupied	glycosylation	sites.	The	generated	glycosylation	sequon	peptides	are	then	
analyzed	by	liquid	chromatography	multiple	reaction	monitoring	mass	spectrometry	
(LC‐MRM‐MS)2.	We	are	using	a	nanoflow	LC	(Eksigent)	coupled	to	a	hybrid	type	QTRAP‐
MS	(ABSciex	3200	QTRAP‐MS)	equipped	with	a	nano‐electrospray	ionization	source.	
With	this	instrumentation	the	triple	quadrupole	mode	MRM‐MS	can	be	combined	
sequentially	with	product	ion	scanning	in	ion	trapping	mode,	or	in	a	MRM	signal	induced	
product	ion	scanning	mode.	MRM	has	the	advantage	that	selected	fragment	transitions	
are	measured	resulting	in	high	specificity,	sensitivity	and	reproducible	signals	for	
quantitation	over	a	wide	range	of	signal	intensities.	In	our	setup,	the	product	ion	
                                                     
2 MRM is also referred to as single reaction monitoring mass spectrometry (SRM MS) and can be considered 
synonymous to MRM. 
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scanning	serves	as	an	additional	scanning	mode	to	confirm	the	sequence	of	the	peptide	
ion	selected	in	the	first	quadrupole	ion	filter.	
2.3.1. Required devices and materials 
- Multiple	Affinity	Removal	LC	Column,	4.6	x	50	mm,	with	proprietary	buffer	
system	(MARS	LC	column	“Human	6”	or	custom	made	“Human	3”	for	IgG,	
transferrin	and	antitrypsin,	Agilent	Technologies)	
- Iodoacetamide	(Sigma	Ultra	grade)	
- Endoproteinase	Asp‐N	(Roche	Diagnostics	GmbH)	
- Trypsin	(Roche	Diagnostics	GmbH,	proteomics	grade)	
- N‐Glycosidase	F	(Roche	Diagnostics	GmbH)	
- Aprotenin	(Roche	Diagnostics	GmbH)	
- 20	mM	ammonium	bicarbonate,	dissolved	in	97	atom	%	H218O,	Cambridge	
Isotope	Laboratories	Inc.)	
- Custom	synthesized,	isotope	labeled	peptides	(≥90%	purity,	HeavyPeptide	Basic	
kit,	Thermo	Electron	Corp.)	
- Multiple	reaction	monitoring‐	(MRM‐)	capable	nano‐LC‐MS	system	
- C18	PepMap	100	trap	column	(300‐μm	inner	diameter	×	5	mm,	Dionex)	
- C18	PepMap100	column	(75‐μm	inner	diameter	×	15	cm,	3	m,	100	Å,	Dionex)	
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2.3.2. Purification of transferrin 
A	sample	aliquot	containing	transferrin	corresponding	to	5	l	human	serum	is	diluted	
ten	times	with	Agilent	buffer	A3	and	loaded	onto	the	MARS	column	according	to	the	
manufacturer	instructions.		Transferrin	will	be	eluted	from	the	column	in	one	step	with	
100%	Agilent	buffer	B.	The	chromatography	can	be	monitored	by	UV	absorption	at	280	
nm	and	the	transferrin	containing	peak	fraction	is	collected.	The	eluate	is	desalted	and	
concentrated	by	TCA	precipitation.	The	samples	are	cooled	on	ice	and	adjusted	to	12%	
TCA	by	adding	0.136	volumes	of	100%	TCA.	The	samples	are	kept	on	ice	for	30	min	or	
ideally	at	‐20°C	overnight	and	centrifuged	for	30	min	at	14000	x	g.	The	supernatants	are	
discarded	and	the	pellet	is	washed	twice	with	300	l	ice‐cold	(‐20	°C)	acetone.	
Centrifuge	for	15	min	at	4	°C	and	14000	x	g	each	time	after	adding	the	acetone.	
	
2.3.3. Proteolytic digestion and deglycosylation of glycopeptides 
The	TCA	precipitated	protein	pellet	is	dissolved	by	sonication	in	250	l	of	0.57	M	Tris‐
HCl,	pH	8.5,	50	mM	DTT	(1M	DTT	diluted	20‐fold	with	0.6	M	Tris‐HCl,	pH	8.5).	Proteins	
are	incubated	for	5	min	at	80°C,	cooled	to	room	temperature	and	cysteine	residues	are	
alkylated	by	adding	63	l	of	1M	iodoacetamide	(5‐fold	excess	over	DTT,	freshly	
prepared).	The	samples	are	incubated	at	room	temperature	in	the	dark	for	40	min	and	
subsequently	desalted	by	TCA	precipitation	(see	section	2.3.2).	The	alkylated	proteins	
are	re‐dissolved	in	50	l	of	20	mM	ammonium	bicarbonate,	containing	10%	acetonitrile.	
Then	0.5	g	of	endoproteinase	Asp‐N	and	0.5	g	of	trypsin	are	added	and	the	sample	is	
incubated	at	37°C	for	16	h.	Proteolysis	is	minimized	by	heating	the	sample	for	5	min	at	
                                                     
3 Buffers A and B are supplied by Agilent together with the MARS column and their composition is proprietary. 
Therefore, we name these buffers “Agilent buffer A” and “Agilent buffer B”, respectively. 
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80°C,	adding	0.5	mol	EDTA	and	100	g	aprotinin.	Then	8	pmol	of	each	standard	
peptide	is	added	and	the	sample	is	lyophilized	overnight.	The	sample	is	re‐dissolved	in	
50	l	of	20	mM	ammonium	bicarbonate	in	95	atom	%	H218O,	1.5	units	of	N‐Glycosidase	F	
(dissolved	in	95	atom	%	H218O)	is	added	and	the	sample	is	digested	at	37°C	for	8	h.	The	
duration	of	the	N‐Glycosidase	F	digestion	was	empirically	optimized	and	it	is	
recommended	to	keep	these	conditions	to	avoid	sample	degradation	or	incomplete	N‐
Glycosidase	F	digestion.	The	reaction	is	stopped	by	heat	inactivation	at	80	°C	for	5	min.	
One	tenth	of	the	sample	is	adjusted	to	20	l	of	0.1%	formic	acid	in	2%	acetonitrile	and	
filtered	through	a	0.22	m	centrifugal	filter	device.	
	
2.3.4. Liquid chromatography multiple reaction monitoring mass spectrometry 
The	sample	is	loaded	on	the	trap	column	and	the	column	is	washed	with	60	μl	of	0.1%	
formic	acid,	2%	acetonitrile.	After	washing,	the	trap	column	is	switched	in	line	to	the	
PepMap	column	and	a	binary	gradient	at	250	nl/min	is	applied	with	Buffer	A	0.1%	
formic	acid,	and	buffer	B	80%	ACN	containing	0.1%	formic	acid.	Buffer	B	is		held	at	14%	
for	3	min,	increased	to	54%	over	102	min	and	to	100%	over	8	min,	held	at	100%	for	12	
min,	and	decreased	to	14%	over	12	min,	and	the	column	is	re‐equilibrated	at	14%	buffer	
B	for	16	min.	The	Asn413	peptides	elute	between	8	and	14	minutes	and	the	Asn611	
peptides	elute	between	22	and	34	minutes	retention	time.	The	parameters	used	for	the	
detection	of	the	transferrin	peptides	were	determined	empirically	with	synthetic	
peptides	and	are	listed	in	Table	1.	
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2.3.5. Calculation of the N‐glycosylation site occupancies 
The	average	counts	per	second	(cps)	for	each	MRM	transition	are	calculated	by	
integrating	the	counts	over	the	time	of	peak	elution	with	the	instrument	acquisition	
software.	The	molar	relative	response	factor	(MRRF)	for	each	peptide	sequence	is	
calculated	by	dividing	the	cps	of	the	target	peptide	to	the	cps	of	the	corresponding	
standard	peptide.		
ܯܴܴܨ ൌ ܿ݌ݏ୘ୟ୰୥ୣ୲	୮ୣ୮୲୧ୢୣܿ݌ݏୗ୲ୟ୬ୢୟ୰ୢ	୮ୣ୮୲୧ୢୣ	
The	percentage	of	site	occupancies	is	calculated	as	follows:	
%	ܽݐ	ܣݏ݊଺ଵଵ ൌ ܯܴܴܨ஽௏்ܯܴܴܨ஽௏் ൅ ܯܴܴܨே௏் ൈ 100	
	
%	ܽݐ	ܣݏ݊ସଵଷ ൌ ܯܴܴܨ஽௄ ൅ܯܴܴܨ஽௄ௌܯܴܴܨ஽௄ ൅ܯܴܴܨ஽௄ௌ ൅ ܯܴܴܨே௄ ൅ܯܴܴܨே௄ௌ ൈ 100	
	
3. O‐GLYCOSYLATION 
Mucin‐type	glycosylation	is	initiated	in	the	Golgi	apparatus	and	is	therefore	not	directly	
involved	in	the	UPR.	However,	mucin‐type	O‐glycosylation	is	involved	in	the	
intracellular	processing	of	glycoproteins	and	contributes	to	their	stability	at	the	cell	
surface.		
	
3.1. Release of O‐glycans by the ‐elimination reaction 
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O‐glycans	linked	to	the	hydroxyamino	acids	Ser	or	Thr	can	be	released	by	mild	alkali	
treatment.	This	mild	alkali	treatment	induces	the	‐elimination	reaction,	releasing	O‐
linked	carbohydrates	from	the	‐carbon	of	Ser	or	Thr	and	leads	to	the	formation	of	2‐
aminopropenoic	acid	or	2‐amino‐2‐butenocic	acid,	respectively	(Figure	1).	A	decrease	of	
Ser	or	Thr	after	mild	alkali	treatment	can	be	monitored	by	amino	acid	analysis,	
providing	further	information	about	the	presence	of	O‐glycosylation	and	the	
hydroxyamino	acid	involved	in	the	O‐glycosyl	linkage	(Hülsmeier	et	al.,	2010;	Hülsmeier	
et	al.,	2002).	The	released	O‐glycans	are	unstable	under	alkaline	conditions	and	undergo	
stepwise	degradation	reactions	termed	“peeling	reaction”.	A	second	‐elimination	
reaction	occurs	at	the	reducing	end	GalNAc	residue,	resulting	in	the	formation	of	a	
furanosyl	compound,	the	Morgan	Elson	chromogen	(Figure	1).	The	“peeling	reaction”	
can	be	minimized	by	including	sodium	borohydride	(NaBH4)	to	the	reaction	mixture,	
thereby	reducing	the	aldehydic	group	of	GalNAc	to	the	corresponding	primary	alcohol	
N‐acetylgalactosaminitol	(GalNAc‐ol).	GalNAc‐ol	is	stable	under	alkaline	conditions.	
Further	GalNAc	can	be	isotopically	labeled	by	using	either	sodium	borodeuterite	
(NaBD4)	or	sodium	borotritiate	as	reducing	agents.	A	2:8(mol:mol)	mixture	of	NaBH4	
and	NaBD4	can	be	used,	which	introduces	a	“fingerprint”	isotope	distribution	into	the	O‐
glycans,	facilitating	the	identification	of	O‐glycans	in	MALDI‐MS	and	alleviating	the	
assignments	of	fragmentation	ion	spectra	by	marking	the	reducing	end	C1	carbohydroxy	
group	(Hülsmeier	et	al.,	2002).	
	
3.1.1. Required devices and materials 
- Sodium	borohydride,	sodium	borodeuterite	(Sigma)	
- Sodium	hydroxide,	purest	available	grade	(Sigma)	
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- Clean	glass	rod	and	glass	tube	
- Methyl	iodide	(ReagentPlus,	99.5%,	Sigma‐Aldrich)	
- sodium	thiosulphate	(Sigma)	
- 2,5‐dihydroxybenzoic	acid		(Fluka)	
	
3.1.2. Reductive ‐elimination 
The	glycoprotein	sample	(1	mg	or	less)	is	lyophilized	in	a	1.5	ml	screw	cap	
polypropylene	vial	and	dissolved	in	200	l	freshly	prepared	0.1	M	sodium	hydroxide,	
containing	0.2	M	NaBH4	and	0.8	M	NaBD4	(prepared	by	mixing	1M	NaBH4	and	1M	NaBD4	
solutions	2:8	by	volume).	The	sample	is	incubated	at	37°C	for	24	h.	Then	further	100	l	
of	0.1	M	sodium	hydroxide,	containing	0.2	M	NaBH4	and	0.8	M	NaBD4	are	added	and	
incubation	continues	for	further	48	h	at	37°C.	The	reaction	is	stopped	by	carefully	
adding	acetic	acid	until	gas	development	ceases.	The	sample	will	be	acidified	to	
approximately	pH	4.	
	
3.1.3. Purification of the ‐eliminated O‐glycans 
A	C18	Sep‐Pak	cartridge	is	conditioned	with	5	ml	methanol,	5	ml	propanol	and	
equilibrated	with	2	times	5	ml	1%	acetic	acid.	A	0.6	ml	Dowex	AG50W‐X12	column	is	
conditioned	with	3	times	5	ml	4	M	HCl	and	washed	with	water	until	the	flow	through	
becomes	neutral.	The	Sep‐Pak	cartridge	is	mounted	on	top	of	the	Dowex	column	and	
both	columns	are	equilibrated	with	3	times	5	ml	of	1%	acetic	acid.	The	‐elimination	
products	are	passed	through	the	combined	columns	and	the	columns	are	washed	twice	
with	2	ml	of	1%	acetic	acid.	The	flow	through	is	collected	into	a	glass	vial	and	dried	
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under	vacuum	evaporation.	Residual	boric	acid	is	removed	by	co‐evaporation	twice	with	
250	l	1%	acetic	acid	in	methanol	and	twice	with	250	l	methanol.	Residual	acetic	acid	
is	removed	by	two	evaporations	with	50	l	of	toluene.	
3.1.4. Permethylation 
The	permethylation	derivatization	is	carried	out	according	to	the	NaOH	method	
(Ciucanu	and	Kerel,	1984).	The	purified	O‐glycans	are	dried	from	100	l	of	10	mM	
triethylamine	to	improve	the	solubility	of	negatively	charged	glycans	as	triethylamine	
salts	in	dimethyl	sulfoxide	(DMSO).	Then,	50	l	DMSO	is	added	and	the	reaction	vial	is	
agitated	for	20	min.	A	120	mg/ml	slurry	of	NaOH	in	DMSO	is	prepared	by	crushing	NaOH	
pellets	with	a	glass	rod	in	a	glass	tube.	The	NaOH	will	not	dissolve	completely	and	
precipitate.	Mixing	of	the	slurry	is	required	prior	application	to	the	derivatization	
reaction.	A	50	l	aliquot	of	the	NaOH/DMSO	slurry	is	added	to	the	reaction	vial	
containing	the	O‐glycans	and	the	vial	is	shaken	for	additional	20	min.	Then,	10	l	of	
methyl	iodide	are	added	twice,	and	the	vial	is	agitated	for	10	min	after	each	addition,	
followed	by	a	final	addition	of	20	l	of	methyl	iodide	and	agitation	of	the	vial	for	further	
20	minutes.	Permethylated	glycans	are	extracted	by	adding	250	l	of	chloroform	and	
500	l	of	1	M	sodium	thiosulphate.	The	vial	is	agitated	thoroughly	and	the	liquid	phases	
are	separated	by	centrifugation.	The	aqueous	phase	is	discarded	and	the	chloroform	
phase,	containing	the	permethylated	O‐glycans	is	washed	10	times	with	1	ml	of	water.	
The	chloroform	phase	is	vacuum	dried	and	the	permethylated	O‐glycans	are	re‐
dissolved	in	50	%	acetonitrile	for	application	to	MALDI‐mass	spectrometry	(MADLI‐MS).	
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3.1.5. MALDI‐MS 
The	MALDI	matrix	is	prepared	by	dissolving	10	mg	2,5‐dihydroxybenzoic	acid	(DHB)	in	
1	ml	of	50	%	acetonitrile,	containing	1	mM	sodium	chloride	(Hülsmeier	et	al.,	2010).	
Aliquots	of	the	permethylated	O‐glycans	are	mixed	on	the	MALDI	plate	with	DHB	matrix	
1:1	(v:v)	and	allowed	to	dry	at	room	temperature.	The	dried	spots	are	re‐crystallized	by	
applying	less	than	0.1	l	of	ethanol.	A	10	l	pipette	tip	is	dipped	into	ethanol	and	some	
solvent	will	be	taken	up	by	capillary	force.	Ethanol	outside	the	tip	is	evaporated	by	
waving	the	tip	in	the	air	for	a	few	seconds.	Then	the	tip	is	placed	over	the	dried	DHB	
spot,	that	the	ethanol	solvent	just	touches	the	MALDI	plate	surface.	The	DHB	crystals	
will	dissolve	quickly	and	are	left	to	air	dry.	As	a	result	an	even	layer	of	DHB	crystals	will	
be	formed,	permitting	sensitive	detection	of	the	analytes.	The	re‐crystallization	can	be	
repeated,	if	necessary.	Additional	DHB	matrix	can	be	added,	if	difficult	samples	are	to	be	
analyzed.	MALDI	mass	spectra	are	recorded	in	positive	ion	mode	and	glycans	are	mainly	
detected	as	their	sodium	ion	adducts,	due	the	presence	of	1	mM	sodium	chloride	in	the	
DHB	matrix.	
	
3.2. Release of O‐glycans by hydrazinolysis 
Releasing	O‐glycans	by	hydrazinolysis	has	the	advantage,	that	the	glycans	are	liberated	
with	a	free	reducing	end	saccharide.	This	allows	subsequent	labeling	with	fluorophores	
like	2AB	or	anthranilic	acid,	facilitating	high	resolution	chromatographic	separation	
combined	with	unparalleled	sensitive	fluorescence	detection	(see	section	2.2.6‐2.2.7,	
Figure	2).	It	is	important	for	this	reaction	to	occur	under	anhydrous	conditions	and	that	
the	sample	is	free	of	salt,	metal	ions,	detergent,	dyes	and	stains.	The	reaction	mechanism	
during	hydrazinolysis	has	not	been	elucidated	so	far.	However,	an	initial	formation	of	a	
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hydrazone	derivative	with	concomitant	release	of	water	seems	to	be	likely.	After	re‐N‐
acetylation	of	the	released	glycans,	acetohydrazone	derivatives	are	formed	and	O‐
glycans	in	unreduced	form	can	be	recovered	after	passage	through	cation	exchange	
resin	and	the	addition	of	Copper‐(II)‐acetate	in	mild	acid	(Patel	et	al.,	1993).	
3.2.1. Required devices and materials 
- Water	and	methanol	rinsed,	oven	dried	250	l	glass	syringe	
- Glass	reaction	vials	
- Lyophilizer	
- Pure	anhydrous	hydrazine	(Ludger	Ltd,	UK)	
- Ice	cold,	saturated	sodium	bicarbonate	solution	
- Acetic	acid	anhydride	(Sigma)	
- Dowex	AG50	[+H‐form]	resin	(Bio‐Rad)	
- Copper‐(II)‐acetate	(Sigma)	
- Supelclean™	ENVI‐18	resin	(Sigma)	
 
3.2.2. Hydrazinolysis 
The	glycoprotein	sample	is	dialyzed	against	0.1%	TFA	and	transferred	to	a	clean	glass	
reaction	vial.	The	sample	is	lyophilized	extensively	for	one	to	three	days,	depending	on	
the	amount	of	protein	(up	to	5	mg	protein).	Then,	anhydrous	hydrazine	is	added	
immediately	using	a	glass	syringe,	pre‐rinsed	with	hydrazine.	Hydrazine	is	added	in	
excess	to	the	sample	to	give	a	less	than	5	mg	protein	per	ml	hydrazine	solution.	The	
reaction	vessel	is	capped	securely	and	mixed	gently	to	bring	the	majority	of	sample	into	
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solution.	The	sample	is	transferred	in	a	heating	block	at	60	°C	and	incubated	for	5	h.	The	
sample	is	cooled	to	room	temperature	and	vacuum	dried	or	lyophilized.	Residual	
hydrazine	can	be	removed	from	the	sample	by	three	times	re‐drying	from	100	l	
methanol	and	finally	evaporation	from	50	l	toluene.	The	vial	is	placed	on	ice	and	100	l	
of	ice‐cold	saturated	sodium‐bicarbonate	solution	is	added,	followed	by	the	addition	of	
twice	10	l	acetic	acid	anhydride4.	The	sample	is	mixed	and	incubated	at	room	
temperature	for	10	min.	Then,	a	second	aliquot	of	acetic	acid	anhydride	is	added	and	the	
incubation	proceeds	for	further	20	min.	The	sample	is	passed	through	a	3	ml	Dowex	
AG50	[+H‐form]	column,	followed	by	4	ml	of	water.	The	eluate	is	collected,	dried	and	re‐
dissolved	in	2	ml	of	1	mM	Copper‐(II)‐acetate	in	1	mM	acetic	acid.	The	sample	is	
incubated	at	room	temperature	for	1	h	and	the	O‐glycans	are	purified	by	passage	
through	a	column	of	2	ml	ENVI‐18	resin	over	1	ml	Dowex	AG50	[+H‐form]	resin,	eluted	
with	water.	The	O‐glycans	are	now	ready	for	2AB‐derivatisation	and	HPLC	analysis	(see	
sections	2.2.6	and	2.2.7).	2AB‐labeled	glycan	can	also	be	subjected	to	permethylation	for	
analysis	by	MALDI‐MS.	In	our	hands,	permethylation	of	2AB‐glycans	leads	to	significant	
higher	signal	intensities	in	MALDI‐MS	compared	to	permethylation	of	alkaline	
borohydride	reduced	glycans.	
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4 From our experience, re-N-acetylation with sodium bicarbonate can lead to partial O-acetylation reactions. O-
acetylation might are not evident in HPLC analyses, but can be detected in MALDI-MS. Here it can serve as an 
indicator for the presence of saccharide in precursor ion scanning experiments. Saccharides would be detected in 
MALDI with a characteristic satellite peak increment of 42 Da. 
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Table	1:	Peptides	used	for	transferrin	glycosylation	sites	Asn413	and	Asn611.	Amino	acids	
containing	the	isotope	label	are	marked	bold:	F,	+10	Da;	L,	+7	Da;	A,	+4	Da.	Due	to	a	
misscleavage	at	Lys414,	two	sets	of	peptides	are	required.	Two	Asn413	sequon	variants	
are	generated	at	approximately	equal	abundance	in	the	reaction	mixture.	The	
fragmentation	conditions	for	each	peptide	were	optimized	empirically	for	maximum	
signal	intensities.	Dwell	time,	time	per	transition;	DP,	declustering	potential;	EP,	
entrance	potential;	CEP,	collision	cell	entrance	potential;	CE,	collision	energy;	CXP,	
collision	cell	exit	potential.	
Designation	 Sequence	 m/z	value	 Q3	ion	
Standard	peptide Target	peptide	
Asn413‐NK	 CGLVPVLAENYNK	 749.4		 742.4	 y9	
Asn413‐NKS	 CGLVPVLAENYNKS 792.9	 785.9	 y10	
Asn413‐DK	 CGLVPVLAENYDK	 755.9	 744.9	 y9	
Asn413‐DKS	 CGLVPVLAENYDKS 799.4	 788.4	 y10	
Asn611‐NVT	 QQQHLFGSNVT	 640.3	 633.3	 b5‐NH3
Asn611‐DVT	 QQQHLFGSDVT	 645.3	 635.3	 b9	
	
Designation	 Dwell	time	 DP	 EP	 CEP	 CE	 CXP	
	 (ms)	 (V)	 (V)	 (V)	 (V)	 (V)	
Asn413‐NK	 100	 40	 9.0	 40	 41	 45	
Asn413‐NKS	 100	 41	 9.5	 43	 44	 48	
Asn413‐DK	 100	 41	 9.0	 40	 41	 45	
Asn413‐DKS	 100	 41	 9.5	 43	 44	 48	
Asn611‐NVT	 150	 40	 9.0	 35	 37	 43	
Asn611‐DVT	 150	 40	 9.0	 35	 37	 44	
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FIGURE LEGENDS 
Figure	1:	The	proposed	reaction	scheme	for	the	‐elimination	reaction	is	exemplified	
with	a	serine	linked	mucin‐type	O‐glycan.	Under	alkaline	conditions	hydroxide	ions	
attack	the	‐carbon	of	the	amino	acid	serine,	inducing	the	liberation	of	the	
oligosaccharide	from	the	‐carbon.	Initially,	water	and	a	free	reducing	end	
oligosaccharide	are	generated	from	the	polypeptide	and	as	a	result	2‐aminopropenoic	
acid	is	formed.	Inclusion	of	borohydride	to	the	reaction	mixture	reduces	the	
oligosaccharide	to	its	corresponding	primary	alcohol	(oligosaccharitol).	Without	
reduction	of	the	oligosaccharide,	the	glycans	would	undergo	a	second	‐elimination	
sequence	and	the	reducing‐end	GalNac	would	form	the	Morgen	Elson	chromogen.	The	
second	‐elimination	is	accelerated,	if	the	‐carbon	is	substituted,	i.e.	participating	in	a	
glycosydic	linkage.	
	
Figure	2:	A	fluorescence	chromatogram	of	2AB‐labeled	O‐linked	glycans	from	bovine	
submaxillary	mucin.	The	O‐glycans	were	released	by	hydrazinolysis,	derivatized	with	2‐
AB	and	subjected	to	normal	phase	HPLC.	The	retention	times	are	converted	into	glucose	
units	(GU)	via	calibration	with	a	2AB‐labeled	dextran	hydrosylate	in	consecutive	runs.	
The	calculation	of	GU	facilitates	the	assignment	of	glycan	structures	by	comparison	with	
published	GU	values.	These	assignments	can	further	be	corroborated	by	digestion	with	
exoglycosidase	enzymes.	For	example,	digestion	of	the	sample	with	sialidase	would	lead	
to	a	reduction	of	the	GlcNAc1‐3[NeuNAc2‐6]GalNAc‐2AB	peak	and	a	corresponding	
increase	of	the	GlcNAc1‐3GalNAc‐2AB	peak.	The	linkage	positions	are	indicated	by	the	
orientation	of	the	substituent	and	are	decoded	in	the	displayed	pictogram.	Anomericity	
is	encoded	as	a	solid	line	for	‐linkage	and	dotted	line	for	‐linkage,	respectively.	The	
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glycan	constituents	are	displayed	in	different	shaped	symbols	according	to	the	figure	
legend.		


